Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04342975 · ClinicalTrials.gov registry record · Phase 2
Protection From Acute Kidney Injury (AKI) With Basis™ Treatment
A Phase 2 study of AKI, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT04342975: Completed Phase 2 study of AKI, sponsored by Mayo Clinic.
NCT04342975 is a Phase 2 study of AKI that has completed, run by Mayo Clinic. The registered enrollment target is 54 participants, below the 78-participant average among 4 other AKI trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04342975, a Phase 2 study of AKI, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a single-center, prospective, randomized, double-blinded, placebo-controlled phase II clinical trial to evaluate the efficacy of "NAD+ supplementation" with Basis™ (Nicotinamide Riboside and Pterostilbene) in preventing acute kidney injury (AKI) in patients undergoing complex aortic aneurysm repair and open aortic arch reconstruction.
Primary Outcome
The primary endpoint will be change in incidence of AKI measured by estimated glomerular filtration rate (eGFR) using the RIFLE criteria.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nicotinamide Riboside + Pterostilbene
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2024-03-14 |
| Phase | Phase 2 |
What the finished NCT04342975 record still lists
NCT04342975 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 78-participant average among 4 other AKI trials with a reported enrollment target (31% lower).
The record links to 1 condition, with AKI appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04342975 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04342975 about?
NCT04342975 is a clinical study titled "Protection From Acute Kidney Injury (AKI) With Basis™ Treatment". This study is a single-center, prospective, randomized, double-blinded, placebo-controlled phase II clinical trial to evaluate the efficacy of "NAD+ supplementation" with Basis™ (Nicotinamide Riboside and Pterostilbene) in preventing acute kidney injury (AKI) in patients undergoing complex aortic an...
What is the current status of trial NCT04342975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2020-12-01. Estimated completion is 2024-03-14.
What conditions does trial NCT04342975 study?
This clinical trial studies the following conditions: AKI.
What interventions are being tested in trial NCT04342975?
The interventions under investigation include: Placebo (DRUG), Nicotinamide Riboside + Pterostilbene (DRUG).
Who is sponsoring clinical trial NCT04342975?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04342975 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AKI
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery
COMPLETED · Phase 2
-
NO During CPB in Neonates to Reduce Risk of AKI
RECRUITING · Phase 3
-
Outpatient Recovery From Acute Kidney Injury Requiring Dialysis - 2
RECRUITING · NA
-
Intraoperative Transesophageal Echocardiography Assessment of Portal Vein Flow and Renal Resistive Index As a Predictor of Acute Kidney Injury After Cardiac Surgery: A Prospective Observational Study
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI